Literature DB >> 29955493

Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature.

Sarah E Grady1, Travis A Marsh2, Allison Tenhouse3, Kelsey Klein4.   

Abstract

INTRODUCTION: Over the past decade, ketamine has been studied for major depressive disorder and bipolar depression. Ketamine is believed to exert its antidepressant properties through N-methyl-D-aspartate receptor antagonism.
METHODS: Study authors completed a literature review of seven randomized controlled trials of ketamine usage in major depressive disorder and bipolar depression.
RESULTS: Ketamine demonstrated a statistically significant improvement over placebo or midazolam in major depressive disorder. Ketamine also exhibited a statistically significant improvement over placebo in bipolar depression. DISCUSSION: Ketamine has shown promise in quickly reducing symptoms in patients with treatment resistant depression and bipolar depression. Using ketamine may be helpful for patients that have exhausted other therapeutic options.

Entities:  

Keywords:  NMDA antagonist; bipolar depression; depression; ketamine

Year:  2018        PMID: 29955493      PMCID: PMC6007654          DOI: 10.9740/mhc.2017.01.016

Source DB:  PubMed          Journal:  Ment Health Clin        ISSN: 2168-9709


  25 in total

1.  Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later.

Authors:  H V Curran; C Morgan
Journal:  Addiction       Date:  2000-04       Impact factor: 6.526

2.  Antidepressant effects of ketamine in depressed patients.

Authors:  R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal
Journal:  Biol Psychiatry       Date:  2000-02-15       Impact factor: 13.382

3.  Ketamine abusers presenting to the emergency department: a case series.

Authors:  A L Weiner; L Vieira; C A McKay; M J Bayer
Journal:  J Emerg Med       Date:  2000-05       Impact factor: 1.484

4.  Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

Authors:  Carlos A Zarate; Nancy E Brutsche; Lobna Ibrahim; Jose Franco-Chaves; Nancy Diazgranados; Anibal Cravchik; Jessica Selter; Craig A Marquardt; Victoria Liberty; David A Luckenbaugh
Journal:  Biol Psychiatry       Date:  2012-01-31       Impact factor: 13.382

5.  GC-MS quantification of ketamine, norketamine, and dehydronorketamine in urine specimens and comparative study using ELISA as the preliminary test methodology.

Authors:  Pai-Sheng Cheng; Chien-Yu Fu; Choung-Huei Lee; Chiareiy Liu; Chun-Sheng Chien
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-02-15       Impact factor: 3.205

6.  Antidepressants modulate the in vitro inhibitory effects of propofol and ketamine on norepinephrine and serotonin transporter function.

Authors:  Yejun Zhao; Lena Sun
Journal:  J Clin Neurosci       Date:  2008-09-23       Impact factor: 1.961

7.  Relative potency of ketamine and S(+)-ketamine in dogs.

Authors:  J C Duque; N Oleskovicz; E C B P Guirro; C A A Valadão; V E Soares
Journal:  J Vet Pharmacol Ther       Date:  2008-08       Impact factor: 1.786

8.  A randomized controlled trial of intranasal ketamine in major depressive disorder.

Authors:  Kyle A B Lapidus; Cara F Levitch; Andrew M Perez; Jess W Brallier; Michael K Parides; Laili Soleimani; Adriana Feder; Dan V Iosifescu; Dennis S Charney; James W Murrough
Journal:  Biol Psychiatry       Date:  2014-04-03       Impact factor: 13.382

9.  Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes.

Authors:  Youssef Hijazi; Roselyne Boulieu
Journal:  Drug Metab Dispos       Date:  2002-07       Impact factor: 3.922

Review 10.  To use or not to use: an update on licit and illicit ketamine use.

Authors:  Jih-Heng Li; Balasingam Vicknasingam; Yuet-Wah Cheung; Wang Zhou; Adhi Wibowo Nurhidayat; Don C Des Jarlais; Richard Schottenfeld
Journal:  Subst Abuse Rehabil       Date:  2011-03-16
View more
  12 in total

1.  Context-Specific Tolerance and Pharmacological Changes in the Infralimbic Cortex-Nucleus Accumbens Shell Pathway Evoked by Ketamine.

Authors:  Gleice Kelli Silva-Cardoso; Manoel Jorge Nobre
Journal:  Neurochem Res       Date:  2021-03-30       Impact factor: 3.996

Review 2.  Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.

Authors:  Rebecca L Dean; Tahnee Marquardt; Claudia Hurducas; Styliani Spyridi; Annabelle Barnes; Rebecca Smith; Philip J Cowen; Rupert McShane; Keith Hawton; Gin S Malhi; John Geddes; Andrea Cipriani
Journal:  Cochrane Database Syst Rev       Date:  2021-10-08

3.  Reduced functional bladder capacity associated with ketamine use.

Authors:  Sergio de P Ramos; Tatiana K Zambonato; Túlio M Graziottin
Journal:  Braz J Psychiatry       Date:  2019-06-10       Impact factor: 2.697

4.  Ketamine Administration Reverses Corticosterone-Induced Alterations in Excitatory and Inhibitory Transmission in the Rat Dorsal Raphe Nucleus.

Authors:  Joanna Sowa; Magdalena Kusek; Bartosz Bobula; Grzegorz Hess; Krzysztof Tokarski
Journal:  Neural Plast       Date:  2019-08-15       Impact factor: 3.599

5.  Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?

Authors:  Nefize Yalin; Allan H Young
Journal:  Neuropsychiatr Dis Treat       Date:  2020-06-09       Impact factor: 2.570

6.  Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study.

Authors:  Chuanjun Zhuo; Feng Ji; Hongjun Tian; Lina Wang; Feng Jia; Deguo Jiang; Ce Chen; Chunhua Zhou; Xiaodong Lin; Jingjing Zhu
Journal:  Brain Behav       Date:  2020-07-03       Impact factor: 2.708

7.  The effect of ketamine on preventing postpartum depression.

Authors:  Mina Alipoor; Marzeyeh Loripoor; Majid Kazemi; Farshid Farahbakhsh; Ali Sarkoohi
Journal:  J Med Life       Date:  2021 Jan-Mar

8.  Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine's antidepressant effects.

Authors:  Valerie J Sydnor; Amanda E Lyall; Suheyla Cetin-Karayumak; Joey C Cheung; Julia M Felicione; Oluwaseun Akeju; Martha E Shenton; Thilo Deckersbach; Dawn F Ionescu; Ofer Pasternak; Cristina Cusin; Marek Kubicki
Journal:  Transl Psychiatry       Date:  2020-12-15       Impact factor: 6.222

9.  An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant Depression.

Authors:  Sherry-Anne Muscat; Glenn Hartelius; Courtenay Richards Crouch; Kevin W Morin
Journal:  Front Psychiatry       Date:  2021-11-24       Impact factor: 4.157

Review 10.  Bipolar depression: a major unsolved challenge.

Authors:  Ross J Baldessarini; Gustavo H Vázquez; Leonardo Tondo
Journal:  Int J Bipolar Disord       Date:  2020-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.